Distinct metabolism of and response to drugs by LSCs
| Metabolic target . | Description . | Therapy, if applicable . | Active and recruiting trials . |
|---|---|---|---|
| Hsp90 | Heat shock protein; protective under cell stress conditions47 | AT13387 | N/A for AML |
| AUY922 (luminespib) | |||
| BIIB028 | |||
| STA-9090 (ganetespib) | |||
| MPC-3100 | |||
| IPI-493 | |||
| SNX-5422 | |||
| NF-κB | Nuclear factor κB; regulates stress response pathways7,48 | Bortezomib | NCT01736943 |
| NCT01534260 | |||
| Choline magnesium trisalicylate | N/A for AML | ||
| Pentoxifylline | N/A for AML | ||
| Glutathione | Redox balance regulator51 | Buthionine sulfoximine | N/A for AML |
| CB-839 | NCT02071927 | ||
| Bcl-2 | B-cell lymphoma 2; regulator of mitochondrial activity and antiapoptotic factor52 | Venetoclax | NCT02670044 |
| NCT02203773 | |||
| S 055746 | NCT02920541 | ||
| Oblimersen | N/A for AML | ||
| IDH1/2 | Isocitrate dehydrogenase; susceptible to perturbations in oxidative phosphorlyation53 | AG221 (IDH2 inhibitor) | NCT02632708 |
| NCT02677922 | |||
| NCT02577406 | |||
| AG120 (IDH1 inhibitor) | NCT02632708 | ||
| NCT02074839 | |||
| AG881 (dual IDH1 and IDH2 inhibitor) | NCT02492737 | ||
| IDH305 (IDH1 inhibitor) | NCT02826642 | ||
| NCT02381886 | |||
| FT-2102 (IDH1 inhibitor) | NCT02719574 | ||
| ALOX-5 | Arachidonate 5-lipoxygenase; potential LSC regulator54 | VIA-2291 | N/A for AML |
| PF-04191834 | |||
| GSK2190915 |
| Metabolic target . | Description . | Therapy, if applicable . | Active and recruiting trials . |
|---|---|---|---|
| Hsp90 | Heat shock protein; protective under cell stress conditions47 | AT13387 | N/A for AML |
| AUY922 (luminespib) | |||
| BIIB028 | |||
| STA-9090 (ganetespib) | |||
| MPC-3100 | |||
| IPI-493 | |||
| SNX-5422 | |||
| NF-κB | Nuclear factor κB; regulates stress response pathways7,48 | Bortezomib | NCT01736943 |
| NCT01534260 | |||
| Choline magnesium trisalicylate | N/A for AML | ||
| Pentoxifylline | N/A for AML | ||
| Glutathione | Redox balance regulator51 | Buthionine sulfoximine | N/A for AML |
| CB-839 | NCT02071927 | ||
| Bcl-2 | B-cell lymphoma 2; regulator of mitochondrial activity and antiapoptotic factor52 | Venetoclax | NCT02670044 |
| NCT02203773 | |||
| S 055746 | NCT02920541 | ||
| Oblimersen | N/A for AML | ||
| IDH1/2 | Isocitrate dehydrogenase; susceptible to perturbations in oxidative phosphorlyation53 | AG221 (IDH2 inhibitor) | NCT02632708 |
| NCT02677922 | |||
| NCT02577406 | |||
| AG120 (IDH1 inhibitor) | NCT02632708 | ||
| NCT02074839 | |||
| AG881 (dual IDH1 and IDH2 inhibitor) | NCT02492737 | ||
| IDH305 (IDH1 inhibitor) | NCT02826642 | ||
| NCT02381886 | |||
| FT-2102 (IDH1 inhibitor) | NCT02719574 | ||
| ALOX-5 | Arachidonate 5-lipoxygenase; potential LSC regulator54 | VIA-2291 | N/A for AML |
| PF-04191834 | |||
| GSK2190915 |
N/A, not applicable.